Advice
following a full submission
lixisenatide (Lyxumia®) is accepted for restricted use within NHS Scotland.
Indication under review: treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
SMC restriction: to use in patients for whom a glucagon-like protein-1 (GLP-1) agonist is appropriate, as an alternative to existing GLP-1 agonists.
Lixisenatide reduces glycosylated haemoglobin (HbA1c) and body weight compared with placebo when used in combination with oral antidiabetic drugs or in combination with basal insulin.
Download detailed advice247KB (PDF)
Medicine details
- Medicine name:
- lixisenatide (Lyxumia)
- SMC ID:
- 903/13
- Indication:
- Treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 September 2013